Skip to content

Author

Philippe Aftimos

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials.

Selective estrogen receptor degraders (SERDs) have emerged as a key therapeutic class in hormone receptor-positive (HR+) breast cancer, combining estrogen receptor (ER) antagonism with direct receptor degradation. Despite this dual mechanism, pivotal trials of SERDs in premenopausal patients-across both metastatic and...

Ana-Maria Dudău, J. Zeghondy, G. Emile et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

No validated biomarkers beyond PD-L1 currently guide immune checkpoint inhibition (ICI) in advanced triple-negative breast cancer (TNBC), and how tumors remodel their microenvironment in response to ICI remains incompletely understood. We perform a temporal analysis of patients with advanced TNBC treated with chemo-imm...

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.